$86.06
0.60.70%
After Hours: 9:13 AM EDT
15 minutes delayed
Comments
Loading...
BioNTech
BNTXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
BioNTech (NASDAQ:BNTX) Stock, Analyst Ratings, Price Targets, Forecasts
BioNTech SE has a consensus price target of $172.32 based on the ratings of 22 analysts. The high is $451 issued by Bryan Garnier on August 11, 2021. The low is $90 issued by JP Morgan on March 22, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on June 26, 2024, June 10, 2024, and June 4, 2024, respectively. With an average price target of $113 between HC Wainwright & Co., there's an implied 31.53% upside for BioNTech SE from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Evercore ISI Group
TD Cowen
BMO Capital
UBS
1calculated from analyst ratings
Analyst Ratings for BioNTech
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/26/2024 | Buy Now | 31.53% | HC Wainwright & Co. | Robert Burns | $113 → $113 | Reiterates | Buy → Buy | Get Alert |
| 06/10/2024 | Buy Now | 31.53% | HC Wainwright & Co. | Robert Burns | $113 → $113 | Reiterates | Buy → Buy | Get Alert |
| 06/04/2024 | Buy Now | 31.53% | HC Wainwright & Co. | Robert Burns | $113 → $113 | Reiterates | Buy → Buy | Get Alert |
| 06/03/2024 | Buy Now | 31.53% | HC Wainwright & Co. | Robert Burns | $113 → $113 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2024 | Buy Now | 31.53% | HC Wainwright & Co. | Robert Burns | $113 → $113 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2024 | Buy Now | 31.53% | HC Wainwright & Co. | Robert Burns | $113 → $113 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2024 | Buy Now | 31.53% | HC Wainwright & Co. | Robert Burns | → $113 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 16.4% | Evercore ISI Group | Cory Kasimov | → $100 | Initiates | → In-Line | Get Alert |
| 05/08/2024 | Buy Now | 31.53% | HC Wainwright & Co. | Robert Burns | $107 → $113 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 14.07% | TD Cowen | Yaron Werber | $95 → $98 | Maintains | Hold | Get Alert |
| 05/07/2024 | Buy Now | 42.01% | BMO Capital | Etzer Darout | $123 → $122 | Maintains | Outperform | Get Alert |
| 04/17/2024 | Buy Now | 24.55% | HC Wainwright & Co. | Robert Burns | → $107 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 17.56% | UBS | Eliana Merle | $110 → $101 | Maintains | Neutral | Get Alert |
| 03/22/2024 | Buy Now | 4.76% | JP Morgan | Jessica Fye | $99 → $90 | Maintains | Underweight | Get Alert |
| 03/21/2024 | Buy Now | 43.17% | BMO Capital | Etzer Darout | $127 → $123 | Maintains | Outperform | Get Alert |
| 03/21/2024 | Buy Now | 99.05% | Canaccord Genuity | Bill Maughan | → $171 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 16.4% | Goldman Sachs | Chris Shibutani | $113 → $100 | Maintains | Neutral | Get Alert |
| 02/23/2024 | Buy Now | 99.05% | Canaccord Genuity | Bill Maughan | → $171 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | 47.83% | BMO Capital | Etzer Darout | → $127 | Initiates | → Outperform | Get Alert |
| 02/21/2024 | Buy Now | 99.05% | Canaccord Genuity | Bill Maughan | → $171 | Reiterates | Buy → Buy | Get Alert |
| 02/20/2024 | Buy Now | 99.05% | Canaccord Genuity | Bill Maughan | $168 → $171 | Maintains | Buy | Get Alert |
| 01/23/2024 | Buy Now | 24.55% | HC Wainwright & Co. | Robert Burns | $133 → $107 | Maintains | Buy | Get Alert |
| 12/01/2023 | Buy Now | 15.24% | JP Morgan | Jessica Fye | $106 → $99 | Downgrade | Neutral → Underweight | Get Alert |
| 11/27/2023 | Buy Now | 54.81% | HC Wainwright & Co. | Robert Burns | → $133 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2023 | Buy Now | 54.81% | HC Wainwright & Co. | Robert Burns | $180 → $133 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 29.2% | Morgan Stanley | Matthew Korn | $110 → $111 | Maintains | Equal-Weight | Get Alert |
| 10/17/2023 | Buy Now | 28.04% | Morgan Stanley | Matthew Korn | $116 → $110 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | 29.2% | HSBC | Yifeng Liu | $124 → $111 | Downgrade | Buy → Hold | Get Alert |
| 08/28/2023 | Buy Now | 109.52% | HC Wainwright & Co. | Robert Burns | → $180 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 109.52% | HC Wainwright & Co. | Robert Burns | $181 → $180 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 35.03% | Morgan Stanley | Matthew Korn | $119 → $116 | Maintains | Equal-Weight | Get Alert |
| 08/01/2023 | Buy Now | 38.52% | Morgan Stanley | Matthew Korn | $119 → $119 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/31/2023 | Buy Now | 38.52% | Morgan Stanley | Matthew Korn | $119 → $119 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/24/2023 | Buy Now | 38.52% | Morgan Stanley | Matthew Korn | $119 → $119 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/17/2023 | Buy Now | 38.52% | Morgan Stanley | Matthew Korn | $119 → $119 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/14/2023 | Buy Now | 44.34% | HSBC | Rajesh Kumar | → $124 | Initiates | → Buy | Get Alert |
| 07/11/2023 | Buy Now | 38.52% | Morgan Stanley | Matthew Korn | $124 → $119 | Maintains | Equal-Weight | Get Alert |
| 06/26/2023 | Buy Now | 44.34% | Morgan Stanley | Matthew Korn | $124 → $124 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/20/2023 | Buy Now | 44.34% | Morgan Stanley | Matthew Korn | → $124 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/16/2023 | Buy Now | 136.29% | Canaccord Genuity | Bill Selesky | → $203 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2023 | Buy Now | 44.34% | Morgan Stanley | Matthew Korn | → $124 | Reiterates | → Equal-Weight | Get Alert |
| 06/09/2023 | Buy Now | 110.69% | HC Wainwright & Co. | Robert Burns | → $181 | Reiterates | → Buy | Get Alert |
| 06/01/2023 | Buy Now | 110.69% | HC Wainwright & Co. | Robert Burns | $198 → $181 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | 130.47% | HC Wainwright & Co. | Robert Burns | $210 → $198 | Maintains | Buy | Get Alert |
| 05/18/2023 | Buy Now | 39.68% | Deutsche Bank | Emmanuel Papadakis | $135 → $120 | Maintains | Hold | Get Alert |
| 05/17/2023 | Buy Now | 97.88% | Redburn Partners | Simon Baker | $165 → $170 | Upgrade | Neutral → Buy | Get Alert |
| 05/09/2023 | Buy Now | 44.34% | Morgan Stanley | Matthew Korn | $150 → $124 | Maintains | Equal-Weight | Get Alert |
| 04/24/2023 | Buy Now | 57.14% | Deutsche Bank | Emmanuel Papadakis | $160 → $135 | Maintains | Hold | Get Alert |
| 04/10/2023 | Buy Now | 48.99% | JP Morgan | Jessica Fye | $142 → $128 | Maintains | Neutral | Get Alert |
| 03/31/2023 | Buy Now | 78.09% | UBS | Eliana Merle | $168 → $153 | Maintains | Neutral | Get Alert |
| 03/30/2023 | Buy Now | 144.44% | HC Wainwright & Co. | Robert Burns | → $210 | Reiterates | → Buy | Get Alert |
| 03/28/2023 | Buy Now | 51.32% | TD Cowen | Yaron Werber | $145 → $130 | Maintains | Market Perform | Get Alert |
| 03/28/2023 | Buy Now | 125.82% | B of A Securities | Tazeen Ahmad | $239 → $194 | Maintains | Buy | Get Alert |
| 03/28/2023 | Buy Now | 74.6% | Morgan Stanley | Matthew Korn | $216 → $150 | Maintains | Equal-Weight | Get Alert |
| 03/28/2023 | Buy Now | 136.29% | Canaccord Genuity | Bill Selesky | $191 → $203 | Maintains | Buy | Get Alert |
| 03/28/2023 | Buy Now | 62.96% | Goldman Sachs | Chris Shibutani | $156 → $140 | Maintains | Neutral | Get Alert |
| 03/23/2023 | Buy Now | 144.44% | HC Wainwright & Co. | Robert Burns | $272 → $210 | Maintains | Buy | Get Alert |
| 02/08/2023 | Buy Now | 65.29% | JP Morgan | Jessica Fye | $148 → $142 | Maintains | Neutral | Get Alert |
| 01/31/2023 | Buy Now | 81.59% | Goldman Sachs | Chris Shibutani | $177 → $156 | Maintains | Neutral | Get Alert |
| 01/24/2023 | Buy Now | 151.43% | Morgan Stanley | Matthew Harrison | $203 → $216 | Maintains | Equal-Weight | Get Alert |
| 12/15/2022 | Buy Now | 178.2% | B of A Securities | Tazeen Ahmad | → $239 | Upgrade | Neutral → Buy | Get Alert |
| 11/11/2022 | Buy Now | 86.24% | Deutsche Bank | Emmanuel Papadakis | $180 → $160 | Maintains | Hold | Get Alert |
| 11/08/2022 | Buy Now | 136.29% | Morgan Stanley | Matthew Harrison | $194 → $203 | Maintains | Equal-Weight | Get Alert |
| 11/08/2022 | Buy Now | 106.03% | Goldman Sachs | Chris Shibutani | $200 → $177 | Maintains | Neutral | Get Alert |
| 10/24/2022 | Buy Now | 53.65% | JP Morgan | Jessica Fye | $183 → $132 | Maintains | Neutral | Get Alert |
| 08/10/2022 | Buy Now | 216.61% | HC Wainwright & Co. | Robert Burns | $283 → $272 | Maintains | Buy | Get Alert |
| 07/29/2022 | Buy Now | 160.74% | SVB Leerink | Daina Graybosch | $223 → $224 | Maintains | Outperform | Get Alert |
| 07/15/2022 | Buy Now | 125.82% | Morgan Stanley | Matthew Harrison | $195 → $194 | Maintains | Equal-Weight | Get Alert |
| 07/13/2022 | Buy Now | 159.57% | SVB Leerink | Daina Graybosch | $253 → $223 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/11/2022 | Buy Now | 229.41% | HC Wainwright & Co. | Robert Burns | $298 → $283 | Maintains | Buy | Get Alert |
| 07/06/2022 | Buy Now | 123.49% | Canaccord Genuity | William Maughan | → $192 | Assumes | → Buy | Get Alert |
| 06/01/2022 | Buy Now | 109.52% | Deutsche Bank | Emmanuel Papadakis | → $180 | Maintains | Hold | Get Alert |
| 05/24/2022 | Buy Now | 139.79% | Goldman Sachs | Chris Shibutani | $255 → $206 | Maintains | Neutral | Get Alert |
| 05/10/2022 | Buy Now | 126.98% | Morgan Stanley | Matthew Harrison | $197 → $195 | Maintains | Equal-Weight | Get Alert |
| 04/12/2022 | Buy Now | 246.87% | HC Wainwright & Co. | Robert Burns | $339 → $298 | Maintains | Buy | Get Alert |
| 04/12/2022 | Buy Now | 129.31% | Morgan Stanley | Matthew Harrison | $217 → $197 | Maintains | Equal-Weight | Get Alert |
| 04/05/2022 | Buy Now | 249.2% | Canaccord Genuity | Arlinda Lee | $450 → $300 | Maintains | Buy | Get Alert |
| 04/01/2022 | Buy Now | 132.8% | Deutsche Bank | Emmanuel Papadakis | → $200 | Maintains | Hold | Get Alert |
| 02/23/2022 | Buy Now | 294.6% | HC Wainwright & Co. | Robert Burns | $366 → $339 | Maintains | Buy | Get Alert |
| 02/01/2022 | Buy Now | 152.59% | Morgan Stanley | Matthew Harrison | $284 → $217 | Maintains | Equal-Weight | Get Alert |
| 02/01/2022 | Buy Now | — | Redburn Partners | Simon Baker | — | Upgrade | Sell → Neutral | Get Alert |
| 01/18/2022 | Buy Now | 230.58% | Morgan Stanley | Matthew Harrison | $294 → $284 | Maintains | Equal-Weight | Get Alert |
| 12/21/2021 | Buy Now | 326.03% | HC Wainwright & Co. | Robert Burns | $360 → $366 | Maintains | Buy | Get Alert |
| 12/16/2021 | Buy Now | 242.22% | Morgan Stanley | Matthew Harrison | — | Initiates | → Equal-Weight | Get Alert |
| 11/10/2021 | Buy Now | 319.04% | HC Wainwright & Co. | Robert Burns | — | Upgrade | Neutral → Buy | Get Alert |
| 11/09/2021 | Buy Now | 161.9% | Deutsche Bank | Emmanuel Papadakis | → $225 | Maintains | Hold | Get Alert |
| 10/22/2021 | Buy Now | 191% | Deutsche Bank | — | — | Initiates | → Hold | Get Alert |
| 10/07/2021 | Buy Now | 167.72% | Jefferies | Akash Tewari | — | Initiates | → Hold | Get Alert |
| 10/05/2021 | Buy Now | 211.95% | SVB Leerink | Daina Graybosch | — | Maintains | Market Perform | Get Alert |
| 08/27/2021 | Buy Now | 249.2% | UBS | Eliana Merle | — | Maintains | Neutral | Get Alert |
| 08/20/2021 | Buy Now | 423.8% | Canaccord Genuity | Arlinda Lee | — | Maintains | Buy | Get Alert |
| 08/13/2021 | Buy Now | 241.05% | SVB Leerink | Daina Graybosch | — | Maintains | Market Perform | Get Alert |
| 08/11/2021 | Buy Now | 424.97% | Bryan Garnier | Olga Smolentseva | — | Upgrade | Neutral → Buy | Get Alert |
| 08/11/2021 | Buy Now | 284.12% | HC Wainwright & Co. | Robert Burns | — | Maintains | Neutral | Get Alert |
FAQ
What is the target price for BioNTech (BNTX) stock?
The latest price target for BioNTech (NASDAQ:BNTX) was reported by HC Wainwright & Co. on June 26, 2024. The analyst firm set a price target for $113.00 expecting BNTX to rise to within 12 months (a possible 31.53% upside). 34 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioNTech (BNTX)?
The latest analyst rating for BioNTech (NASDAQ:BNTX) was provided by HC Wainwright & Co., and BioNTech reiterated their buy rating.
When was the last upgrade for BioNTech (BNTX)?
The last upgrade for BioNTech SE happened on May 17, 2023 when Redburn Partners raised their price target to $170. Redburn Partners previously had a neutral for BioNTech SE.
When was the last downgrade for BioNTech (BNTX)?
The last downgrade for BioNTech SE happened on December 1, 2023 when JP Morgan changed their price target from $106 to $99 for BioNTech SE.
When is the next analyst rating going to be posted or updated for BioNTech (BNTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioNTech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioNTech was filed on June 26, 2024 so you should expect the next rating to be made available sometime around June 26, 2025.
Is the Analyst Rating BioNTech (BNTX) correct?
While ratings are subjective and will change, the latest BioNTech (BNTX) rating was a reiterated with a price target of $113.00 to $113.00. The current price BioNTech (BNTX) is trading at is $85.91, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.